Latest & greatest articles for atrial fibrillation

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on atrial fibrillation or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on atrial fibrillation and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for atrial fibrillation

761. Percutaneous occlusion of the left atrial appendage for atrial fibrillation

Percutaneous occlusion of the left atrial appendage for atrial fibrillation Percutaneous occlusion of the left atrial appendage for atrial fibrillation Percutaneous occlusion of the left atrial appendage for atrial fibrillation National Institute for Health and Clinical Excellence Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation National Institute for Health (...) and Clinical Excellence. Percutaneous occlusion of the left atrial appendage for atrial fibrillation. London: National Institute for Health and Clinical Excellence (NICE). Interventional Procedure Guidance 181. 2006 Authors' objectives This study aims to assess the current evidence on percutaneous occlusion of the left atrial appendage for atrial fibrillation. Authors' conclusions 1 Guidance 1.1 Current evidence on the safety and efficacy of percutaneous occlusion of the left atrial appendage (LAA

Health Technology Assessment (HTA) Database.2006

762. Atrial fibrillation: the management of atrial fibrillation

Atrial fibrillation: the management of atrial fibrillation Atrial fibrillation: the management of atrial fibrillation Atrial fibrillation: the management of atrial fibrillation National Institute for Health and Clinical Excellence Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation National Institute for Health and Clinical Excellence. Atrial fibrillation (...) : the management of atrial fibrillation. London: National Institute for Health and Clinical Excellence (NICE). Clinical Guideline 36. 2006 Authors' objectives The aim of this guideline is to assess the management of atrial fibrillation. Project page URL Indexing Status Subject indexing assigned by CRD MeSH Atrial Fibrillation /diagnosis /therapy /ultrasonography /drug therapy Language Published English Country of organisation England Address for correspondence MidCity Place, 71 High Holborn, London WC1V 6NA

Health Technology Assessment (HTA) Database.2006

763. Pulmonary vein isolation for treatment of atrial fibrillation

Pulmonary vein isolation for treatment of atrial fibrillation Pulmonary vein isolation for treatment of atrial fibrillation Pulmonary vein isolation for treatment of atrial fibrillation BlueCross BlueShield Association Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. The BlueCross BlueShield Association Technology Evaluation Center website ( ) includes the most recent 3 (...) years of TEC Assessments. To request older reports, please use the “contact us” feature on the website. Citation BlueCross BlueShield Association. Pulmonary vein isolation for treatment of atrial fibrillation. Chicago: BlueCross BlueShield Association (BCBS). TEC Assessment 21(1). 2006 Authors' objectives The objective of this assessment is to determine whether pulmonary vein isolation (PVI) improves health outcomes when used as an alternative to pharmacologic treatment for patients

Health Technology Assessment (HTA) Database.2006

764. The Magic of Magnesium as an Adjunct in Atrial Fibrillation

The Magic of Magnesium as an Adjunct in Atrial Fibrillation The Magic of Magnesium as an Adjunct in Atrial Fibrillation « Sinai EM Journal Club Emergency Medicine Discussion Forum The Magic of Magnesium as an Adjunct in Atrial Fibrillation Dinali did a stellar job this month at Journal Club; not only was her talk thought-provoking and clinically relevant, but I learned more about the history of of than I would have ever thought possible. This month’s JC was primarily about Davey and Teubner’s (...) AEM paper on using Magnesium sulfate as an adjunct to “usual care” for rate control in atrial fibrillation ( ). We also touched upon some data from an all-Greek study in the Int’l Journal of Cardiology on Mg alone vs diltiazem alone in A-fib ( ). Davey and Taubner looked at 199 Australians with rapid afib in this prospective, randomized, double-blinded, placebo-controlled trial. They got “standard rate-reduction agents” plus placebo, or te same agents plus 20 mEq of magnesium sulfate infused over

Sinai EM Journal Club2006

765. Clopidogrel plus aspirin was inferior to oral anticoagulation for preventing vascular events in atrial fibrillation

Clopidogrel plus aspirin was inferior to oral anticoagulation for preventing vascular events in atrial fibrillation Clopidogrel plus aspirin was inferior to oral anticoagulation for preventing vascular events in atrial fibrillation | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name (...) or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Clopidogrel plus aspirin was inferior to oral anticoagulation for preventing vascular events in atrial fibrillation Article Text Therapeutics Clopidogrel plus aspirin was inferior to oral anticoagulation for preventing vascular events in atrial fibrillation Statistics from

Evidence-Based Medicine (Requires free registration)2006

766. Circumferential pulmonary-vein ablation for chronic atrial fibrillation.

Circumferential pulmonary-vein ablation for chronic atrial fibrillation. 16510747 2006 03 02 2006 03 07 2016 08 03 1533-4406 354 9 2006 Mar 02 The New England journal of medicine N. Engl. J. Med. Circumferential pulmonary-vein ablation for chronic atrial fibrillation. 934-41 We conducted a randomized, controlled trial of circumferential pulmonary-vein ablation for the treatment of chronic atrial fibrillation. A total of 146 patients with a mean (+/-SD) age of 57+/-9 years who had chronic (...) atrial fibrillation were randomly assigned to receive amiodarone and undergo two cardioversions during the first three months alone (the control group) or in combination with circumferential pulmonary-vein ablation. Cardiac rhythm was assessed with daily telephonic transmissions for one year. The left atrial diameter and the severity of symptoms were assessed at 12 months. Among the 77 patients assigned to undergo circumferential pulmonary-vein ablation, ablation was repeated because of recurrent

NEJM2006

767. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.

Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. 16765759 2006 06 12 2006 06 22 2016 11 24 1474-547X 367 9526 2006 Jun 10 Lancet (London, England) Lancet Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE (...) W): a randomised controlled trial. 1903-12 Oral anticoagulation therapy reduces risk of vascular events in patients with atrial fibrillation. However, long-term monitoring is necessary and many patients cannot achieve optimum anticoagulation. We assessed whether clopidogrel plus aspirin was non-inferior to oral anticoagulation therapy for prevention of vascular events. Patients were enrolled if they had atrial fibrillation plus one or more risk factor for stroke, and were randomly allocated

Lancet2006

768. Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension.

Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension. 16968848 2006 09 13 2006 09 15 2016 10 17 1538-3598 296 10 2006 Sep 13 JAMA JAMA Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension. 1242-8 Atrial fibrillation (AF) is associated with increased risk of mortality and cardiovascular events (...) , particularly stroke, making prevention of new-onset AF a clinical priority. Although the presence and severity of electrocardiographic left ventricular hypertrophy (LVH) appear to predict development of AF, whether regression of electrocardiographic LVH is associated with a decreased incidence of AF is unclear. To test the hypothesis that in-treatment regression or continued absence of electrocardiographic LVH during antihypertensive therapy is associated with a decreased incidence of AF, independent

JAMA2006

769. High-intensity focused ultrasound for atrial fibrillation in association with other cardiac surgery (IPG184)

High-intensity focused ultrasound for atrial fibrillation in association with other cardiac surgery (IPG184) High-intensity focused ultrasound for atrial fibrillation in association with other cardiac surgery | Guidance and guidelines | NICE High-intensity focused ultrasound for atrial fibrillation in association with other cardiac surgery Interventional procedures guidance [IPG184] Published date: July 2006 Share Save Guidance and for this guidance. Your responsibility This guidance represents

National Institute for Health and Clinical Excellence - Interventional Procedures2006

770. Percutaneous radiofrequency ablation for atrial fibrillation (IPG168)

Percutaneous radiofrequency ablation for atrial fibrillation (IPG168) Percutaneous radiofrequency ablation for atrial fibrillation | Guidance and guidelines | NICE Percutaneous radiofrequency ablation for atrial fibrillation Interventional procedures guidance [IPG168] Published date: April 2006 Share Save Guidance and for this guidance. Your responsibility This guidance represents the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement

National Institute for Health and Clinical Excellence - Interventional Procedures2006

771. A randomised controlled trial and cost-effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in people aged 65 and over

A randomised controlled trial and cost-effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in people aged 65 and over A randomised controlled trial and cost-effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in people aged 65 and over: The SAFE study Journals Library An error has occurred

NIHR HTA programme2005

772. Does magnesium offer any additional benefit in patients having anti-arrhythmic treatment for atrial fibrillation following cardiac surgery?

Does magnesium offer any additional benefit in patients having anti-arrhythmic treatment for atrial fibrillation following cardiac surgery? BestBets: Does magnesium offer any additional benefit in patients having anti-arrhythmic treatment for atrial fibrillation following cardiac surgery? Does magnesium offer any additional benefit in patients having anti-arrhythmic treatment for atrial fibrillation following cardiac surgery? Report By: Anish Patel, Jagan Rao - Cardiothoracic Registrars Search (...) checked by J Desmond - Cardiothoracic Registrar RCS Institution: Department of Cardiothoracic Surgery, Freeman Hospital, Freeman Road, Newcastle-upon-Tyne Date Submitted: 15th April 2003 Date Completed: 29th July 2005 Last Modified: 6th May 2003 Status: Green (complete) Three Part Question In [patients undergoing cardiac surgery, going into atrial fibrillation] is [the addition of magnesium] more effective than standard therapy alone in [cardioverting or controlling ventricular rate]. Clinical

BestBETS2005

773. Atrial fibrillation had a negative impact on quality of life, and treatment with an implantable cardioverter defibrillator with atrial therapies helped patients regain a sense of normalcy

Atrial fibrillation had a negative impact on quality of life, and treatment with an implantable cardioverter defibrillator with atrial therapies helped patients regain a sense of normalcy Atrial fibrillation had a negative impact on quality of life, and treatment with an implantable cardioverter defibrillator with atrial therapies helped patients regain a sense of normalcy | Evidence-Based Nursing This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies (...) . Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Atrial fibrillation had a negative impact on quality of life, and treatment

Evidence-Based Nursing (Requires free registration)2005

774. Is Sotalol more effective than standard beta-blockers for the prophylaxis of atrial fibrillation during cardiac surgery

Is Sotalol more effective than standard beta-blockers for the prophylaxis of atrial fibrillation during cardiac surgery BestBets: Is Sotalol more effective than standard beta-blockers for the prophylaxis of atrial fibrillation during cardiac surgery Is Sotalol more effective than standard beta-blockers for the prophylaxis of atrial fibrillation during cardiac surgery Report By: Anish Patel and Joel Dunning - Cardiothoracic Registrar Search checked by Joel Dunning - Cardiothoracic Registrar RCS (...) Institution: Department of Cardiothoracic Surgery, Freeman Hospital. Newcastle upon Tyne Date Submitted: 4th September 2002 Date Completed: 27th May 2005 Last Modified: 27th May 2005 Status: Green (complete) Three Part Question In [patients undergoing cardiac surgery] is prophylactic [Sotalol compared to conventional � Blockers] more effective in reducing the incidence of [atrial fibrillation]. Clinical Scenario You are updating a protocol for the prophylaxis of atrial fibrillation after cardiac surgery

BestBETS2005

775. Ximelagatran was non-inferior to warfarin in preventing stroke and systemic embolism in atrial fibrillation

Ximelagatran was non-inferior to warfarin in preventing stroke and systemic embolism in atrial fibrillation Ximelagatran was non-inferior to warfarin in preventing stroke and systemic embolism in atrial fibrillation | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search (...) for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Ximelagatran was non-inferior to warfarin in preventing stroke and systemic embolism in atrial fibrillation Article Text Therapeutics Ximelagatran was non-inferior to warfarin in preventing stroke and systemic embolism in atrial fibrillation Free Carl van Walraven , MD Statistics from Altmetric.com

Evidence-Based Medicine (Requires free registration)2005

776. Anticoagulation before cardioversion of acute atrial fibrillation in the emergency department

Anticoagulation before cardioversion of acute atrial fibrillation in the emergency department BestBets: Anticoagulation before cardioversion of acute atrial fibrillation in the emergency department Anticoagulation before cardioversion of acute atrial fibrillation in the emergency department Report By: Katherine Potier - Specialist Registrar in Emergency Medicine Search checked by Richard Parris - Locum Consultant Institution: Manchester Royal Infirmary Date Submitted: 17th September 2004 Date (...) Completed: 12th April 2005 Last Modified: 6th January 2005 Status: Green (complete) Three Part Question In a patient with [acute atrial fibrillation undergoing cardioversion in the emergency department] does [anticoagulation immediately before cardioversion] [reduce the incidence of thrombo-embolism]? Clinical Scenario A 58 year old man presents to the emergency department with a 24 hour history of new onset AF. You decide to cardiovert him in the department (chemically or electrically) and wonder

BestBETS2005

777. Anticoagulation post- cardioversion of acute atrial fibrillation in the emergency department

Anticoagulation post- cardioversion of acute atrial fibrillation in the emergency department BestBets: Anticoagulation post-cardioversion of acute atrial fibrillation in the emergency department Anticoagulation post-cardioversion of acute atrial fibrillation in the emergency department Report By: Katherine Potier - Specialist Registrar, Emergency Medicine Search checked by Richard Parris - Locum ED Consultant Institution: Emergency Department, Royal Bolton Hospital Date Submitted: 17th (...) September 2004 Date Completed: 12th April 2005 Last Modified: 6th January 2005 Status: Green (complete) Three Part Question In a [patient with acute atrial fibrillation who has cardioverted to sinus rhythm] does [anticoagulation post-cardioversion] [reduce the incidence of thromboembolic complications]? Clinical Scenario A 45 year old man who presented to your emergency department with new onset AF has been successfully chemically cardioverted. You wonder whether he needs anti-coagulating on discharge

BestBETS2005

778. Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation.

Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation. CONTEXT: Recent trials have found that ximelagatran and warfarin are equally effective in stroke prevention for patients with atrial fibrillation. Because ximelagatran can be taken in a fixed, oral dose without international normalized ratio monitoring and may have a lower risk of hemorrhage, it might improve quality-adjusted survival compared with dose-adjusted warfarin. OBJECTIVE: To compare quality (...) -adjusted survival and cost among 3 alternative therapies for patients with chronic atrial fibrillation: ximelagatran, warfarin, and aspirin. DESIGN: Semi-Markov decision model. PATIENTS: Hypothetical cohort of 70-year-old patients with chronic atrial fibrillation, varying risk of stroke, and no contraindications to anticoagulation therapy. MAIN OUTCOME MEASURES: Quality-adjusted life-years (QALYs) and costs in US dollars. RESULTS: For patients with atrial fibrillation but no additional risk factors

JAMA2005

779. Sodium channel mutations and susceptibility to heart failure and atrial fibrillation.

Sodium channel mutations and susceptibility to heart failure and atrial fibrillation. CONTEXT: Dilated cardiomyopathy (DCM), a genetically heterogeneous disorder, causes heart failure and rhythm disturbances. The majority of identified DCM genes encode structural proteins of the contractile apparatus and cytoskeleton. Recently, genetic defects in calcium and potassium regulation have been discovered in patients with DCM, implicating an alternative disease mechanism. The full spectrum of genetic (...) 1987 and 2004. Relatives underwent screening echocardiography and electrocardiography and DNA sample procurement. MAIN OUTCOME MEASURE: Correlation of identified mutations with cardiac phenotype. RESULTS: Refined locus mapping revealed SCN5A, encoding the cardiac sodium channel, as a candidate gene. Mutation scans identified a missense mutation (D1275N) that cosegregated with an age-dependent, variably expressed phenotype of DCM, atrial fibrillation, impaired automaticity, and conduction delay

JAMA2005 Full Text: Link to full Text with Trip Pro

780. Rhythm vs. rate control of atrial fibrillation meta-analysed by number needed to treat

Rhythm vs. rate control of atrial fibrillation meta-analysed by number needed to treat Rhythm vs rate control of atrial fibrillation meta-analysed by number needed to treat Rhythm vs rate control of atrial fibrillation meta-analysed by number needed to treat Kumana C R, Cheung B M, Cheung G T, Ovedal T, Pederson B, Lauder I J CRD summary This review looked at rate control versus rhythm control for atrial fibrillation. The authors found that rate control was associated with a lower incidence (...) of hospitalisation, but there were little other differences in outcomes. They concluded that rate control was preferable. There were a number of problems with the review and the conclusion may not, therefore, be reliable. Authors' objectives To compare the effects of rate control versus rhythm control for the treatment of atrial fibrillation (AF). Searching PubMed, MEDLINE and the Cochrane Library were searched; the search terms were given. Only studies with an English abstract were eligible for inclusion. Study

DARE.2005